LivaNova (NASDAQ:LIVN) Lowered to Buy Rating by StockNews.com

LivaNova (NASDAQ:LIVN - Get Free Report) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a report issued on Wednesday.

Several other brokerages have also issued reports on LIVN. Robert W. Baird lifted their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Needham & Company LLC restated a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Baird R W raised shares of LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. Finally, Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, LivaNova presently has a consensus rating of "Buy" and an average target price of $69.17.

LivaNova Price Performance

Shares of NASDAQ:LIVN traded down $0.24 on Wednesday, hitting $46.75. The company's stock had a trading volume of 132,393 shares, compared to its average volume of 609,976. The company has a market capitalization of $2.54 billion, a PE ratio of 111.31 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a 50-day simple moving average of $51.32 and a 200 day simple moving average of $50.92. LivaNova has a 1 year low of $43.15 and a 1 year high of $64.47.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in LIVN. Sanctuary Advisors LLC purchased a new stake in LivaNova in the third quarter worth approximately $219,000. Geode Capital Management LLC raised its stake in LivaNova by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock valued at $70,676,000 after buying an additional 8,331 shares during the last quarter. XTX Topco Ltd bought a new position in shares of LivaNova during the 3rd quarter valued at $550,000. Point72 DIFC Ltd boosted its stake in shares of LivaNova by 75,799.6% in the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company's stock worth $9,531,000 after buying an additional 181,161 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock worth $109,914,000 after acquiring an additional 806,374 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.